336 related articles for article (PubMed ID: 24778155)
1. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
[TBL] [Abstract][Full Text] [Related]
2. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
[TBL] [Abstract][Full Text] [Related]
4. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
[TBL] [Abstract][Full Text] [Related]
5. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
6. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Sharma P; Sachdeva MUS; Naseem S; Sreedharanunni S; Das R; Malhotra P; Varma N
Int J Lab Hematol; 2022 Jun; 44(3):518-523. PubMed ID: 35142061
[TBL] [Abstract][Full Text] [Related]
7. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
8. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
10. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
11. Flow Cytometry Assessment of CD26
Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
[TBL] [Abstract][Full Text] [Related]
12. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
13. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
14. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
[TBL] [Abstract][Full Text] [Related]
15. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
17. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
18. CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Gu Y; Chen T; Meng Z; Gan Y; Xu X; Lou G; Li H; Gan X; Zhou H; Tang J; Xu G; Huang L; Zhang X; Fang Y; Wang K; Zheng S; Huang W; Xu R
Blood; 2012 Dec; 120(24):4829-39. PubMed ID: 23074277
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing CML LSCs from HSCs using CD26.
Jiang X
Blood; 2014 Jun; 123(25):3851-2. PubMed ID: 24948622
[TBL] [Abstract][Full Text] [Related]
20. miRNome profiling of LSC-enriched CD34
Ruiz MS; Sánchez MB; Bonecker S; Furtado C; Koile D; Yankilevich P; Cranco S; Custidiano MDR; Freitas J; Moiraghi B; Pérez MA; Pavlovsky C; Varela AI; Ventriglia V; Sánchez Ávalos JC; Larripa I; Zalcberg I; Mordoh J; Valent P; Bianchini M
Front Pharmacol; 2020; 11():612573. PubMed ID: 33569005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]